These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33085537)

  • 1. Anti-IFNαR Mabs for the treatment of systemic lupus erythematosus.
    Goulden B; Isenberg D
    Expert Opin Biol Ther; 2021 Apr; 21(4):519-528. PubMed ID: 33085537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus.
    Gensous N; Lazaro E; Blanco P; Richez C
    Expert Rev Clin Immunol; 2024; 20(1):21-30. PubMed ID: 37800604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of anifrolumab for use in adults with systemic lupus erythematosus.
    Ahmed AA; Osman N; Furie R
    Expert Rev Clin Immunol; 2022 Nov; 18(11):1095-1106. PubMed ID: 36083692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?
    Kalunian KC
    Lupus; 2016 Sep; 25(10):1097-101. PubMed ID: 27497254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review.
    Liu Z; Cheng R; Liu Y
    Front Immunol; 2022; 13():996662. PubMed ID: 36211347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE.
    Bao A; Petri MA; Fava A; Kang J
    Lupus Sci Med; 2023 Dec; 10(2):. PubMed ID: 38114267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.
    Tanaka Y; Tummala R
    Mod Rheumatol; 2021 Jan; 31(1):1-12. PubMed ID: 32814461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date.
    Felten R; Scher F; Sagez F; Chasset F; Arnaud L
    Drug Des Devel Ther; 2019; 13():1535-1543. PubMed ID: 31190735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations.
    Anderson E; Furie R
    Immunotherapy; 2020 Apr; 12(5):275-286. PubMed ID: 32237942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type I interferon antagonists in clinical development for lupus.
    Paredes JL; Niewold TB
    Expert Opin Investig Drugs; 2020 Sep; 29(9):1025-1041. PubMed ID: 32700979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
    Furie R; Khamashta M; Merrill JT; Werth VP; Kalunian K; Brohawn P; Illei GG; Drappa J; Wang L; Yoo S;
    Arthritis Rheumatol; 2017 Feb; 69(2):376-386. PubMed ID: 28130918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
    Vital EM; Merrill JT; Morand EF; Furie RA; Bruce IN; Tanaka Y; Manzi S; Kalunian KC; Kalyani RN; Streicher K; Abreu G; Tummala R
    Ann Rheum Dis; 2022 Jul; 81(7):951-961. PubMed ID: 35338035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development.
    Cruciani C; Gatto M; Iaccarino L; Doria A; Zen M
    Expert Opin Investig Drugs; 2024 Aug; 33(8):801-814. PubMed ID: 38958085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.
    Baker T; Sharifian H; Newcombe PJ; Gavin PG; Lazarus MN; Ramaswamy M; White WI; Ferrari N; Muthas D; Tummala R; Morand EF; Furie RA; Vital EM; Chamberlain C; Platt A; Al-Mossawi H; Brohawn PZ; Csomor E
    Ann Rheum Dis; 2024 Jul; 83(8):1018-1027. PubMed ID: 38569851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anifrolumab treatment improves patient-reported quality of life and decreases disease activity and corticosteroid use in patients with systemic lupus erythematosus: A qualitative study in Denmark.
    Troldborg A; Remkus L; Eek D; Deleuran B
    Lupus; 2024 Aug; 33(9):962-973. PubMed ID: 38901042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anifrolumab for systemic lupus erythematosus: A clinical study of Japanese patients in Kanazawa University Hospital.
    Fushida N; Horii M; Oishi K; Matsushita T
    J Dermatol; 2024 Apr; 51(4):607-611. PubMed ID: 37929294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Efficacy and Safety of Anifrolumab in Moderate-to-Severe Systemic Lupus Erythematosus.
    Cingireddy AR; Ramini N; Cingireddy AR
    Cureus; 2024 Jul; 16(7):e63966. PubMed ID: 39104974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood.
    Günther C; Wolf C; Fennen L; Rösing S; Beissert S; Aringer M; Lee-Kirsch MA
    Front Immunol; 2023; 14():1253279. PubMed ID: 37809086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice.
    Tanaka Y
    RMD Open; 2023 Aug; 9(3):. PubMed ID: 37597847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.